Bioage Phase 1 BGE 102

#1

BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile

Key Points

  • BGE-102, an oral brain-penetrant NLRP3 inhibitor, produced up to an 86% reduction in hs-CRP in obese participants and drove potent IL-1β inhibition (~90–98%) with IL-6 decreases up to 70–78%, with 87% (60 mg) and 93% (120 mg) of subjects reaching CRP <2 mg/L.
  • BioAge reported a clean phase I safety profile with mostly mild-to-moderate, self-limited adverse events, no dose-limiting toxicities, no serious adverse events or drug-related discontinuations, and no observed neutropenia, thrombocytopenia, or infections.
  • BioAge plans a larger cardiovascular phase IIa proof-of-concept—four arms totaling 160 patients testing placebo and 30 mg, 60 mg, and 90 mg once daily for 12 weeks (primary endpoint: percent change in CRP)—and a separate phase II study in diabetic macular edema to assess intraocular IL-6 suppression.
2 Likes